This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (4)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: While we applaud Dr Engel's¹ assessment of the importance of suppressive antiviral therapy for genital herpes, we believe he has made several errors in his comparative analysis of the effectiveness of acyclovir, famciclovir, and valacyclovir hydrochloride. The data Engel uses to compare these drugs are derived from separate randomized clinical trials with markedly different patient populations performed more than a decade apart. Patients enrolled in the acyclovir study by Mattison et al² conducted in 1985 had a median frequency of recurrence of 13, for the valacyclovir study conducted by Patel et al³ a decade later it was 8, and for the famciclovir study more than 12 recurrences in 2 years.⁴ The median times to first recurrence in the placebo groups in the acyclovir, valacyclovir, and famciclovir studies were 23, 20, and 47 days, respectively, a 2-fold difference. As it is clear that severity of infection influences the . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Long-term Suppression of Genital Herpes

JAMA. ;280():928-929.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The potential role of suppressive therapy for sex partners in the prevention of neonatal herpes: a health economic analysis
Barnabas et al.
Sex. Transm. Infect. 2002;78:425-429.
ABSTRACT | FULL TEXT